Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that management will be participating in the H.C. Wainwright 23^rd Annual Global investment Conference being held virtually on September 13-15, 2021. Management will deliver a company presentation and will be available for one-on-one meetings with investors. The recorded presentation will be available on demand beginning Monday, September 13^th on the Investors section of Anebulo’s website.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit www.anebulo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005053/en/